KEWAUNEE SCIENTIFIC CORP /DE/ — Form 8-K
Filed August 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Kewaunee reported FY2026 (ended April 30, 2026) revenue of $282.0M vs. $240.5M in FY2025 (+17.2%), EBITDA of $22.4M vs. $21.6M (+3.7%), and net earnings of $9.6M. The company reduced long-term debt by ~$20M and fully repaid NuAire seller notes, improving debt-to-equity from 0.99 to 0.61. Backlog declined to $165.9M from $214.6M due to completion of large international projects. Lab Products Group (formerly Domestic segment) revenue was $214.9M (+19.8%; includes full-year NuAire post-November 1, 2024 acquisition). International segment revenue was $67.1M (+9.9%). The company repositioned its International segment to focus on turnkey Indian turnkey projects and hired new international leadership (Jorge Santos, VP Sales; Lucia Lema, Director Operations) to expand emerging markets.
Why this rating
Strong revenue/debt reduction against $70M market cap, but backlog decline and modest EBITDA growth offset gains; integration ongoing.
See more from August 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.